Oncoinvent A

Oncoinvent A Current Ratio

The Current Ratio of Oncoinvent A (ONCIN.OL) as of Nov 7, 2026 is 3.81. In the previous year, Current Ratio was 4.34 — a change of -12.33% (lower).

Current Ratio

3.81

YoY

-12.33%

Last updated:

Current Ratio of Oncoinvent A is 2025 3.81 . Current Ratio of Oncoinvent A was 2024 4.34 . It decreases by -12.33% lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Oncoinvent A Stock analysis

What does Oncoinvent A do? Oncoinvent ASA is a radiopharmaceutical company based in Oslo, Norway, operating within the Health Care sector. Listed on 13 December 2024, the firm employs 46 people and focuses on developing alpha-emitting radiotherapeutics for cancer patients. Its primary product, Radspherin, is an alpha-emitting radioactive microsphere therapy designed to treat metastatic cancers in body cavities. This suspension of calcium carbonate microspheres labelled with Radium-224 targets residual micro-metastases on intracavitary surfaces and in liquids after surgery, aiming to spare deeper organs from harmful radiation doses. Oncoinvent A is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Oncoinvent A stock

Current Ratio of Oncoinvent A is 3.81 in 2025.

Current Ratio of Oncoinvent A changed from 4.34 to 3.81, representing a -12.33% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Ratio Oncoinvent A since 2006 – with annual values, charts, and detailed analysis.

The Current Ratio measures a company's ability to pay short-term obligations. A ratio above 1 indicates that current assets exceed current liabilities.

Current Ratio = Current Assets / Current Liabilities

A 'good' varies by industry and company stage. On Eulerpool, you can compare Current Ratio's Oncoinvent A with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Oncoinvent A

All Key Metrics — Oncoinvent A